Search

The article addresses the attention to sexual diversity, specifically to women who have sex with women. It emphasizes the importance of providing comprehensive care to LGBTQ+ individuals, including information about sexual practices to assess the risk of sexually transmitted infections. It mentions the lack of knowledge and discrimination towards this group, as well as the specific health needs they face. It also addresses the importance of asking about gender identity and sexual practices in primary care consultations, using non-sexist language. It mentions the lack of information and awareness about the risks of sexually transmitted infections among women who have sex with women and the need for awareness campaigns. Additionally, it mentions the importance of addressing reproductive and health aspects in medical consultations, such as contraception and cancer screening. It also mentions the need for vaccination against hepatitis A in cases of unprotected sexual practices. The article provides recommendations for practicing safe sex during menstruation and mentions the importance of using barrier protection methods, such as condoms, when engaging in sexual activities with objects or sex toys. It also suggests the use of natural rubber latex sheets, dental dams, cut condoms, or kitchen plastic wrap during orogenital and oroanal sex to protect against vaginal fluids. It advises against brushing teeth prior to oral sex and recommends using latex gloves or finger cots during digital stimulation or penetration. Additionally, it mentions that certain sexual practices, such as fisting, are considered high-risk and recommends the use of single-use latex or nitrile gloves. Finally, it suggests seeking medical attention in case of symptoms or injuries and provides bibliography related to the sexual health of lesbian, bisexual, and other women who have sex with women. [Extracted from the article]

The article presents a case study of a 58-year-old Hispanic male presented with blurry vision in his left eye for approximately two weeks. The artcile discusses that his medical history is significant for having chronic kidney disease which resulted in a kidney transplant one year earlier and is currently undergoing dialysis; and his blood pressure is now under control.

Sexual dysfunction is common in patients with long-term neurological conditions. Nurses are well placed to engage patients in discussions about any sexual problems they may be experiencing. This article outlines the different types and causes of sexual dysfunction in patients with long-term neurological conditions, and identifies potential treatment options and practical advice to offer patients. [ABSTRACT FROM AUTHOR]

An approach to the management of sexual problems and options for referral or advice are described, and case histories are used to illustrate typical presentations. Further training possibilities are listed for those doctors interested in learning more about this work. [ABSTRACT FROM AUTHOR]

The article discusses how the orphan drug eculizumab changed the way physicians manage paroxysmal nocturnal hemoglobinuria (PNH). The symptoms of PNH include anemia, fatigue and erectile dysfunction. According to Wendell Rosse of Duke University, eculizumab can prevent the breakdown of red blood cells and eliminate many of the symptoms of PNH. Peter Hillmen of the Leeds Teaching Hospitals National Health Service (NHS) Trust in England attests that eculizumab has changed PNH treatment.

This article examines the prevalence, causes, identification, assessment and treatment options for men with erectile dysfunction. Erectile dysfunction is thought to affect one in ten men across the UK and is often a consequence of pathology and/or pharmacology. Treatment can be offered to all patients, but the keys to management are identification, accurate assessment and focused therapy. Nurses are well placed to identify and support men who have this distressing problem. [ABSTRACT FROM AUTHOR]

Erectile dysfunction is caused by physiological, psychological and sociocultural influences. This article discusses the relevance of erectile dysfunction to men with a learning disability. Erectile dysfunction is likely to be a hidden problem and an unmet health need for many men with a learning disability. Because of the paucity of published research in this area, the authors draw on their nursing experiences. They suggest a person-centred approach should be used to address the needs of these men, giving consideration to the sensitive nature of the problem. [ABSTRACT FROM AUTHOR]

The article focuses on developments in the field of sexual medicine in general and erectile dysfunction (ED) in particular. The availability of three well tolerated oral phosphodiesterase type 5 inhibitors (PDE51s) now means that the majority of patients can be safely and effectively managed in primary care. There are many reasons why ED should be managed in primary care. General practitioners regularly manage all the common comorbid conditions such as diabetes, hypertension, hyperlipidaemia, cardiovascular disease, depression and lower urinary tract symptoms. PDE51s were developed for daily dosing in the treatment of hypertension and ischaemic heart disease.

The article provides information about the need of the optometrists to be aware of potential side effects of Viagra and other medications used to treat erectile dysfunction (ED) in the U.S. The etiology of ED typically involves both organic and psychogenic factors. ED is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance.

This article discusses penile diseases. While erectile dysfunction (ED) is extremely common, particularly as men get older. Men who are circumcised develop a thicker epithelium on the head of the penis with a corresponding loss of sensation, and although this has been proposed as a potential treatment for premature ejaculation there is no proof this works. Proponents of circumcision point to the lower rate of penile cancer in circumcised men (there are alternative epidemiological explanations for this) and also to the lower risk of urinary tract infections in uncircumcised male children. INSET: Practical points.

Presents information on the sale of the impotence drug Viagra in Australia as of July 1999. Federal Government's decision to exclude the drug from the Pharmaceutical Benefits Scheme; Public acceptance of the drug seen as slow; Australian men's shyness at dealing with impotency; Low demand for Viagra; Results experienced by patients. INSET: Patients Report Mixed Results, by Dr. Malcolm Clark.

Reports that the American Academy of Ophthalmology (AAO) is monitoring the effects of Pfizer Inc.'s impotence drug sildenafil citrate called Viagra on ocular function. Concerns about reports of transient blue-tinged vision and increased light sensitivity phenomena on Viagra users; Risk of the drug in patients with retinitis pigmentosa.

The article presents information on prostate cancer (PCa). It mentions the signs and symptoms of the disease which include impotence, difficulty urinating and blood in the semen. It discusses the treatment for advanced PCa such as hormone therapy and chemotherapy. It also cites the role of a pharmacist in educating patients with PCa.

The article presents questions and answers related to men's health. A person inquires about the treatment of patients with prostatic symptoms but normal uroflow rates. Another asks about the association between erectile dysfunction and cardiovascular disease. Another inquiry regarding radical prostatectomy is also answered.

The article focuses on issues related to sexual dysfunction in older men. As they grow older, men witness a series of complex sexual changes and chronic diseases. The prevalence of erectile dysfunction, arousal, osteoarthritis and osteoporosis are some of the major changes in the sexual functions among older men.

Reports on the disclosure of latest drug discovery achievements at annual symposium held at American Chemical Society national meetings in Anaheim, California. Introduction of agents for frailty, erectile dysfunction, dermal scarring and thrombosis from researchers at pharmaceutical companies; Career development of the medicinal chemist; Discovery of a series of novel compounds that can potentially benefit patients with age-related functional decline.

The article offers information on EnoSTIM, a natural solution for erectile dysfunction (ED), developed by Nexira.

The article presents a case study of a 54-year-old male who had peripheral visual disturbances in his right eye. It states that the patient's history indicates that he took tadalafil as medication for erectile dysfunction and snored loudly at night. It also mentions that the patient was diagnosed with non-arteritic ischemic optic neuropathy (NAION) and advised to discontinue using tadalafil.

The article discusses research published in the 2010 issue of the journal "Annals of Internal Medicine" entitled "Sexually transmitted diseases among users of erectile dysfunction drugs: analysis of claims data," by A.B. Jena and colleagues. The study found that the rate of sexually transmitted diseases (STDs) including HIV infection was higher in men who use drugs to treat erectile dysfunction than those who did not take the drugs.

The article examines marketing of the brand name anti-impotence drug Viagra by the pharmaceutical industry firm Pfizer Inc. Sales of the drug, one of the most profitable in industry history, declined for the first time in 2009, forcing the company to raise prices. The effects of the loss of patent exclusivity in 2012, when Viagra will face competition from generic drugs, are discussed. INSET: Cialis Plans to Party On.

The article focuses on the declining popularity of anti-impotence drug Viagra of Pfizer. It is said that the brand became a pop-culture lexicon and gave Pfizer 1.9 billion a year in sales. But the brand will lose it market exclusivity due to looming competition from cheaper generic versions of the drug. The drug has already suffered decline in worldwide sales in 2009 by 2% amid the global recession. INSETS: Cialis Plans to Party On;LIPITOR'S FINAL DAYS.

The article examines the dangers of counterfeit pharmaceuticals. Topics covered include how counterfeiters opted to manufacture erectile dysfunction (ED) drugs because of their popularity and costliness, how heroin has been discovered in pills that appear to be generic oxycodone, and counterfeit fentanyl produced in Mexico being the deadliest counterfeit pills.

The article discusses research published in "The American Journal of Clinical Nutrition" on the link between consumption of flavonoid-rich diets in men and reduced risk of experiencing erectile dysfunction.

The article focuses on the study on the possible eye complication of the intake of Viagra and Cialis drugs, an erectile dysfunction drugs. A study has confirmed no significant vision problems or retinal problems caused by taking Viagra and Cialis for at least over a six-month period. Though claims such as mild and transient blurred vision, blue-tinged vision and altered light perception were connected to these drugs, researchers disclose no cumulative impact in taking the drugs for six months.

A letter to the editor is presented in response to an article about the erectile dysfunction after prostate cancer treatment by Robert McConkey in the November 18, 2015 issue.

The article focuses on the implications of phosphodiesterase type 5 (PDE5), a drug intended for erectile dysfunction (ED), to non-arteritic anterior ischemic optic neuropathy (NAION). According to a study, several cases of NAION have already been recorded from people who are using PDE5. However, the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO) have emphasized the illegitimacy of the said report, but advised the public to have precaution when taking the drugs.

The article focuses on a study that showed that approximately 1 in 6 men with vasculogenic erectile dysfunction had documented asymptomatic coronary artery disease (CAD). According to Charalambos Vlachopoulos of the Department of Cardiology at the Athens Medical School in Greece, erectile dysfunction is sometimes the first manifestation of a generalized disease before CAD has become clinically evident.

The article offers comments of chief of ophthalmology George A. Cioffi regarding health risks of erectile dysfunction medications. According to him, since these medications may lead to harmful effects on the optic nerve of patient, a prior discussion with the patients regarding the use of these drugs is essential. He asserts that physicians should be cautious while dealing with patients of repetitive optic nerve head hemorrhage. It also refers to demographics in the context.

The article reports on the relation of erectile dysfunction and infection with cytomegalovirus in men with diabetes. Set of men were presented in an experiment to identify the connection between infection-induced inflammation and endothelial dysfunction. Results show that such condition is evident among men with elevated high-sensitivity C-reactive protein and fibrinogen levels.

The article reports on the plan to the National Football League not to renew contracts with erectile-dysfunction drug advertisements. The drugs used televised sports as a way to communicate their message to men in a context that helps reduce any stigma attached to taking the pills. The league has also a self-imposed ban on health-care sponsorship and advertising in 2003.

Reports on the association of erectile-dysfunction (ED) drug use with eye damage. Information on ED drugs associated with eye damage; Impact of adverse drug reactions on the sales and prescriptions of ED drugs; Extent of competition in the pharmaceutical market.

Focuses on the possible impact of the action taken by the U.S. Food and Drug Administration (FDA) against pharmaceutical company Pfizer regarding its television advertisement for the erectile-dysfunction medication Viagra. Examples of advertisement for other erectile-dysfunction medications available in the U.S.; Plan of acting FDA Commissioner Lester Crawford to increase regulation of prescription drug advertising; Issue over the inaction of FDA against food supplements.

Reports on the marketing strategy undertaken by pharmaceutical firm Pfizer for the treatment of erectile dysfunction (ED). Stigma of ED to men; Outcome of the efforts of the company to promote Viagra; Rise of competition for the treatment of ED.

This article presents solutions to readers queries related to Erectile Dysfunction. There is evidence of a causative link on several levels, epidemiological, clinical and basic science. Epidemiologically, the association between prostate disorders and ED was initially considered coincidental, due to confounding factors such as age and cardiovascular disease. Earlier studies such as the Massachusetts Male Aging Study did not identify prostate disorders as a risk factor for ED. This study used validated questionnaires (14,254 men) and showed a strong correlation between increasing severity of lower urinary tract symptoms and the prevalence of ED.

Reports on the search by pharmaceutical companies GlaxoSmithKline and Schering-Plough in October 2004 for advertising agencies that will handle the advertising and marketing of their erectile-dysfunction (ED) drug Levitra. Competition faced by Levitra from Cialis, an ED drug co-marketed by Eli Lilly & Co. and Icos; Change in advertising agencies with the entry of Schering-Plough as marketing partner for the drug; Advertising work done by agency Quantum Group for the drug.

Presents information on men in the marketing industry. Food consumption of men compared to women; Prevalence of erectile dysfunction in men ages 40 to 70 years old; Percentage of men who purchase their own clothes.

The article answers the question related to reasons for an upgoing plantar response after a brain injury and invites answers from readers of the periodical "Update" on questions related to inulin, erectile dysfunction, rare diseases, ringworm and other medical aspects. The primitive reflexes are primarily protective in nature and include an upgoing plantar response, which is essentially a withdrawal response to pain. This and other primitive reflexes persist in infants until myelination of the nervous system is complete, and the effect of the upper motor neurones causes suppression of these reflexes. The plantar response therefore becomes downgoing for this reason, and, with adoption of an upright stance, helps maintain tonus in the foot and leg.

The article presents information on an advertising campaign created by Healthy Grey Village for the erectile-dysfunction drug Cialis developed by pharmaceutical giant Eli Lilly Co. and biotechnology partner Icos Corp. Within days of Eli Lilly and Icos Corp. receiving an approval letter from the U.S. Food and Drug Administration for their the erectile-dysfunction drug Cialis, the two will launch a $100 million advertising campaign. The advertising campaign is Lilly's best attempt to play catch-up to GlaxoSmithKline and Bayer's Levitra, which hit the market in August, and Pfizer's powerhouse brand Viagra, which has a five-year head start on both. Lilly has already increased the $50 million budget it had set aside for the launch. Television advertising campaign will appear on key prime-time shows on the major networks and selected sporting events. The Cialis campaign will play off its main point of differentiation. It remains effective for up to 36 hours, where Viagra and Levitra last about four hours, though Levitra can start to work as quickly as 16 minutes. Thus Healthy Grey Village's tagline for the campaign plays up the romantic angle: When a tender moment turns into the right moment, you'll be ready.

Reports on the release of erectile dysfunction drug Cialis in February 2003. Comparison of the effectiveness of Cialis to Viagra; Prediction of world market for erectile dysfunction drugs; Side effects.

Reports on the efforts of Pfizer to maintain its sales of Viagra, the anti-impotency drug. Statistics on sales of the drug in 1998 and early 1999; Plans to market the drug in other countries, besides the United States; Expectations that Viagra will dominate the anti-impotency drug market.

Reports on the effect Viagra, the impotency treatment, had on Vivus, a company which marketed its own anti-impotency drug treatment. Statistics on the financial problems Vivus had after Viagra became available; Efforts to improve the company's status in 1999.

Reports on a research on arginase, an enzyme that has tremendous effect on nitric acid (NO) production in the body. Research by scientists from the University of Pennsylvania and Boston University Medical School; Hope that arginase may serve as a possible target for impotence drugs.

Explains that numerous books are quickly being published as a result of the approval of the impotence drug Viagra. Simon & Schuster publishing `The Virility Solution,' by Steven Lamm and Gerald Secor Couzens; Publishers waiting for United States Food and Drug Administration approval in order to publish; List of several mass market paperbacks also being released.

The article reviews a web site on erectile dysfunction and benign prostatic hyperplasia created by the pharmaceutical firm Eli Lilly and Company which is located at www.menshealthanswers.co.uk.